Characteristics of patients eligible for CLL3/CLL8(FCR) comparison
| Characteristic . | CLL3 . | CLL8(FCR) . | P . |
|---|---|---|---|
| n | 110 | 126 | |
| Trial entry (calendar year) | 2000 (1996-2002) | 2005 (2003-2006) | < .001 |
| Sex, female/male (%) | 15/95 (14/86) | 37/89 (29/71) | .004 |
| Age, y | 52 (30-60) | 53 (30-60) | .049 |
| IGHV unfavorable (%) | 70 (64) | 85 (68) | .54 |
| FISH karyotype (hierarchical model) | .18 | ||
| 11q- ± others (%) | 26 (24) | 38 (30) | |
| +12 ± others (except 11q-) (%) | 16 (15) | 9 (7) | |
| 13q- single (%) | 34 (31) | 46 (37) | |
| Others (including normal) (%) | 34 (31) | 33 (26) | |
| Binet stage A, B, C (%) | 16, 62, 31 (15, 57, 28) | 4, 83, 39 (3, 66, 31) | .007 |
| Time from diagnosis, mo | 12 (0-156) | 18 (0-160) | .18 |
| Serum thymidine kinase, U/L | 15.0 (3.0-469) | 18.9 (2.8-259) | .18 |
| β2M, mg/L | 3.3 (0-10) | 2.7 (1.2-7.3) | .008 |
| White blood count > 50/nL (%) | 60/110 (55) | 88/126 (70) | .015 |
| Proportion of patients undergoing complete study treatment (%) | 90/110 (82) | 104/126 (83) | 1.0 |
| Observation time of surviving patients, y | 8.3 (0.4-11.5) | 4.7 (0.3-6.2) |
| Characteristic . | CLL3 . | CLL8(FCR) . | P . |
|---|---|---|---|
| n | 110 | 126 | |
| Trial entry (calendar year) | 2000 (1996-2002) | 2005 (2003-2006) | < .001 |
| Sex, female/male (%) | 15/95 (14/86) | 37/89 (29/71) | .004 |
| Age, y | 52 (30-60) | 53 (30-60) | .049 |
| IGHV unfavorable (%) | 70 (64) | 85 (68) | .54 |
| FISH karyotype (hierarchical model) | .18 | ||
| 11q- ± others (%) | 26 (24) | 38 (30) | |
| +12 ± others (except 11q-) (%) | 16 (15) | 9 (7) | |
| 13q- single (%) | 34 (31) | 46 (37) | |
| Others (including normal) (%) | 34 (31) | 33 (26) | |
| Binet stage A, B, C (%) | 16, 62, 31 (15, 57, 28) | 4, 83, 39 (3, 66, 31) | .007 |
| Time from diagnosis, mo | 12 (0-156) | 18 (0-160) | .18 |
| Serum thymidine kinase, U/L | 15.0 (3.0-469) | 18.9 (2.8-259) | .18 |
| β2M, mg/L | 3.3 (0-10) | 2.7 (1.2-7.3) | .008 |
| White blood count > 50/nL (%) | 60/110 (55) | 88/126 (70) | .015 |
| Proportion of patients undergoing complete study treatment (%) | 90/110 (82) | 104/126 (83) | 1.0 |
| Observation time of surviving patients, y | 8.3 (0.4-11.5) | 4.7 (0.3-6.2) |